# PeptideScanner FDA enforcement reports Published: 2026-08-25 Source snapshot: 2026-08-12 Reports: 22 > This PeptideScanner lane is a bounded, dated FDA enforcement-report snapshot connected through an exact openFDA application-number annotation. It is not a medical alert or complete recall-lifecycle tracker, does not establish current product or recall status, does not identify affected lots, and does not provide medical guidance. ## D-0723-2026 - Report date: 2026-07-08 - FDA classification: Class II - Source status: Ongoing - Recalling firm: Lupin Pharmaceuticals Inc\. - Exact applications: ANDA214457 - Peptide profiles: glucagon - Source-reported reason: CGMP deviation: OOS result observed for the Gliding Force functionality test during 12-month long term stability testing\. - Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0723-2026%22&limit=1 ## D-0541-2026 - Report date: 2026-05-27 - FDA classification: Class II - Source status: Ongoing - Recalling firm: Lupin Pharmaceuticals Inc\. - Exact applications: ANDA215421 - Peptide profiles: liraglutide - Source-reported reason: Presence of particulate matter: a white thread-like structure in the cartridge - Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0541-2026%22&limit=1 ## D-0519-2026 - Report date: 2026-05-13 - FDA classification: Class II - Source status: Ongoing - Recalling firm: Teva Pharmaceuticals USA, Inc - Exact applications: ANDA210317 - Peptide profiles: octreotide - Source-reported reason: Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U\.S Food and Drug Administration \(FDA\) inspection at the contract manufacturer\. - Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0519-2026%22&limit=1 ## D-0422-2026 - Report date: 2026-04-15 - FDA classification: Class II - Source status: Ongoing - Recalling firm: Cipla USA, Inc\. - Exact applications: NDA215395 - Peptide profiles: lanreotide - Source-reported reason: Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure\. - Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0422-2026%22&limit=1 ## D-0423-2026 - Report date: 2026-04-15 - FDA classification: Class II - Source status: Ongoing - Recalling firm: Cipla USA, Inc\. - Exact applications: ANDA217193 - Peptide profiles: lanreotide - Source-reported reason: Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure\. - Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0423-2026%22&limit=1 ## D-0404-2026 - Report date: 2026-04-01 - FDA classification: Class II - Source status: Ongoing - Recalling firm: Teva Pharmaceuticals USA, Inc - Exact applications: ANDA210317 - Peptide profiles: octreotide - Source-reported reason: Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U\.S Food and Drug Administration \(FDA\) inspection at the contract manufacturer\. - Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0404-2026%22&limit=1 ## D-0405-2026 - Report date: 2026-04-01 - FDA classification: Class II - Source status: Ongoing - Recalling firm: Teva Pharmaceuticals USA, Inc - Exact applications: ANDA210317 - Peptide profiles: octreotide - Source-reported reason: Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U\.S Food and Drug Administration \(FDA\) inspection at the contract manufacturer\. - Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0405-2026%22&limit=1 ## D-0406-2026 - Report date: 2026-04-01 - FDA classification: Class II - Source status: Ongoing - Recalling firm: Teva Pharmaceuticals USA, Inc - Exact applications: ANDA210317 - Peptide profiles: octreotide - Source-reported reason: Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U\.S Food and Drug Administration \(FDA\) inspection at the contract manufacturer\. - Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0406-2026%22&limit=1 ## D-0290-2026 - Report date: 2026-01-21 - FDA classification: Class II - Source status: Ongoing - Recalling firm: Cipla USA, Inc\. - Exact applications: NDA215395 - Peptide profiles: lanreotide - Source-reported reason: Presence of Particulate Matter\. - Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0290-2026%22&limit=1 ## D-1178-2023 - Report date: 2023-10-04 - FDA classification: Class III - Source status: Terminated - Recalling firm: Tolmar, Inc\. - Exact applications: NDA021379 - Peptide profiles: leuprolide - Source-reported reason: Superpotent Drug - Higher than expected levels of leuprolide acetate in the constituted product\. - Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-1178-2023%22&limit=1 ## D-0058-2023 - Report date: 2022-11-16 - FDA classification: Class I - Source status: Terminated - Recalling firm: Viatris Inc - Exact applications: ANDA079198 - Peptide profiles: octreotide - Source-reported reason: Presence of Particulate Matter: Product complaint for the presence of glass particles in a syringe\. - Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0058-2023%22&limit=1 ## D-0884-2022 - Report date: 2022-05-25 - FDA classification: Class II - Source status: Completed - Recalling firm: Cardinal Health Inc\. - Exact applications: BLA125469 - Peptide profiles: dulaglutide - Source-reported reason: TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions - Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0884-2022%22&limit=1 ## D-0773-2021 - Report date: 2021-09-01 - FDA classification: Class II - Source status: Terminated - Recalling firm: Eli Lilly & Company - Exact applications: BLA125469 - Peptide profiles: dulaglutide - Source-reported reason: Labeling: Label error on declared strength - autoinjector devices labeled as 0\.75 mg / 0\.5 mL actually contain 1\.5 mg / 0\.5 mL of product\. - Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0773-2021%22&limit=1 ## D-0417-2021 - Report date: 2021-06-02 - FDA classification: Class II - Source status: Terminated - Recalling firm: Cardinal Health Inc\. - Exact applications: NDA202811 - Peptide profiles: linaclotide - Source-reported reason: CGMP Deviations: Intermittent exposure to temperature excursion during storage\. - Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0417-2021%22&limit=1 ## D-0536-2021 - Report date: 2021-06-02 - FDA classification: Class II - Source status: Terminated - Recalling firm: Cardinal Health Inc\. - Exact applications: NDA213051 - Peptide profiles: semaglutide - Source-reported reason: CGMP Deviations: Intermittent exposure to temperature excursion during storage\. - Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0536-2021%22&limit=1 ## D-0618-2021 - Report date: 2021-04-21 - FDA classification: Class II - Source status: Terminated - Recalling firm: Novo Nordisk Inc - Exact applications: NDA206321 - Peptide profiles: liraglutide - Source-reported reason: Temperature Abuse: product samples were stored at temperatures below 32\* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors\. - Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0618-2021%22&limit=1 ## D-0622-2021 - Report date: 2021-04-21 - FDA classification: Class II - Source status: Terminated - Recalling firm: Novo Nordisk Inc - Exact applications: NDA022341 - Peptide profiles: liraglutide - Source-reported reason: Temperature Abuse: product samples were stored at temperatures below 32\* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors\. - Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0622-2021%22&limit=1 ## D-1287-2014 - Report date: 2014-05-07 - FDA classification: Class II - Source status: Terminated - Recalling firm: AbbVie Inc - Exact applications: NDA020517 - Peptide profiles: leuprolide - Source-reported reason: Defective Delivery System: Some Lupron Depot Kits may contain a syringe with a potentially defective LuproLoc needle stick protection device\. - Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-1287-2014%22&limit=1 ## D-1288-2014 - Report date: 2014-05-07 - FDA classification: Class II - Source status: Terminated - Recalling firm: AbbVie Inc - Exact applications: NDA020517 - Peptide profiles: leuprolide - Source-reported reason: Defective Delivery System: Some Lupron Depot Kits may contain a syringe with a potentially defective LuproLoc needle stick protection device\. - Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-1288-2014%22&limit=1 ## D-1289-2014 - Report date: 2014-05-07 - FDA classification: Class II - Source status: Terminated - Recalling firm: AbbVie Inc - Exact applications: NDA020263 - Peptide profiles: leuprolide - Source-reported reason: Defective Delivery System: Some Lupron Depot Kits may contain a syringe with a potentially defective LuproLoc needle stick protection device\. - Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-1289-2014%22&limit=1 ## D-1290-2014 - Report date: 2014-05-07 - FDA classification: Class II - Source status: Terminated - Recalling firm: AbbVie Inc - Exact applications: NDA020708 - Peptide profiles: leuprolide - Source-reported reason: Defective Delivery System: Some Lupron Depot Kits may contain a syringe with a potentially defective LuproLoc needle stick protection device\. - Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-1290-2014%22&limit=1 ## D-1291-2014 - Report date: 2014-05-07 - FDA classification: Class II - Source status: Terminated - Recalling firm: AbbVie Inc - Exact applications: NDA020517 - Peptide profiles: leuprolide - Source-reported reason: Defective Delivery System: Some Lupron Depot Kits may containin a syringe with a potentially defective LuproLoc needle stick protection device\. - Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-1291-2014%22&limit=1